Want to see CHRS full AI Analyst Report?
CHRS Stock Chart & Stats
$1.37
$0.05(3.90%)
At close: 4:00 PM EDT
$1.37
$0.05(3.90%)
Day’s Range― - ―
52-Week Range$0.94 - $2.62
Previous CloseN/A
Volume367.62K
Average Volume (3M)1.53M
Market Cap
$154.50M
Enterprise Value$165.61M
Total Cash (Recent Filing)$105.31M
Total Debt (Recent Filing)$37.71M
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Nov 09, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.02
Shares Outstanding154,500,960
10 Day Avg. Volume1,634,904
30 Day Avg. Volume1,534,313
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.80
Price to Sales (P/S)4.05
P/FCF Ratio-1.23
Enterprise Value/Market Cap1.07
Enterprise Value/Revenue3.25
Enterprise Value/Gross Profit5.12
Enterprise Value/Ebitda-1.12
Forecast
1Y Price Target
$7.75Price Target Upside465.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.89
Revenue Forecast (FY)$60.81M
Bulls Say, Bears Say
Bulls Say
LOQTORZI Commercial GrowthLOQTORZI is showing measurable commercial traction, supported by higher sales, new patient starts, and improving treatment duration. Continued quarterly growth would provide a more durable revenue base, strengthen the oncology franchise, and improve operating leverage as adoption expands.
Sustained Cost ReductionThe sustained reduction in R&D and SG&A indicates a leaner operating structure rather than a single-period cost action. Lower recurring expenses can extend financial runway, reduce the revenue needed to support operations, and improve the company’s ability to focus capital on oncology growth and development.
Debt And Liability ImprovementSubstantial debt and legacy-liability reductions simplify the balance sheet and reduce obligations tied to the divested biosimilar business. The new financing structure also extends maturities, giving management more flexibility to fund operations and advance the pipeline while commercial revenues develop.
Bears Say
Severe Cash BurnLarge negative operating and free cash flow show that the business is not currently self-funding. Continued cash consumption can require additional financing, cost reductions, or stronger commercial performance, increasing execution and dilution risk over the next several quarters.
Unstable Earnings BaseThe sharp revenue decline and swing from profit to substantial loss demonstrate limited earnings stability and operating leverage. An unstable revenue base makes forecasting more difficult, raises dependence on successful product execution, and leaves less capacity to absorb setbacks in commercialization or development.
Clinical And Regulatory UncertaintyImportant pipeline opportunities remain dependent on early clinical signals becoming durable efficacy evidence and ultimately supporting regulatory progress. If later analyses weaken the current findings, expected growth catalysts could be delayed or lost, leaving greater reliance on LOQTORZI sales.
Coherus Biosciences News
CHRS FAQ
What was Coherus Biosciences’s price range in the past 12 months?
Coherus Biosciences lowest stock price was $0.94 and its highest was $2.62 in the past 12 months.
What is Coherus Biosciences’s market cap?
Coherus Biosciences’s market cap is $154.50M.
When is Coherus Biosciences’s upcoming earnings report date?
Coherus Biosciences’s upcoming earnings report date is Nov 09, 2026 which is in 18 days.
How were Coherus Biosciences’s earnings last quarter?
Coherus Biosciences released its earnings results on Aug 05, 2026. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.25 by $0.03.
Is Coherus Biosciences overvalued?
According to Wall Street analysts Coherus Biosciences’s price is currently Undervalued.
Does Coherus Biosciences pay dividends?
Coherus Biosciences does not currently pay dividends.
What is Coherus Biosciences’s EPS estimate?
Coherus Biosciences’s EPS estimate is -0.22.
How many shares outstanding does Coherus Biosciences have?
Coherus Biosciences has 154,500,960 shares outstanding.
What happened to Coherus Biosciences’s price movement after its last earnings report?
Coherus Biosciences reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.25. Following the earnings report the stock price went down -2.027%.
Which hedge fund is a major shareholder of Coherus Biosciences?
Currently, no hedge funds are holding shares in CHRS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Coherus Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.75 (465.69% Upside)
$7.75 (465.69% Upside)
Hedge Fund Trend
Increased
By 24.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.37%
12-Months-Change
Fundamentals
Return on Equity
-181.73%
Trailing 12-Months
Asset Growth
-56.50%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Coherus Biosciences
Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neulasta; YUSIMRY, an equivalent to Humira, prescribed for inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease, which are characterized by heightened tumor necrosis factor (TNF) production; and CIMERLI, a Lucentis biosimilar aimed at treating specific ophthalmic disorders such as neovascular age-related macular degeneration, macular edema, and diabetic retinopathy. Beyond its commercial products, Coherus maintains a robust pipeline of investigational immunotherapies. This includes LOQTORZI, a novel, next-generation programmed death receptor-1 (PD-1) inhibitor; Casdozokitug, a recombinant human immunoglobulin G1 (IgG1) monoclonal antibody designed to target interleukin 27; CHS-114, a highly specific human afucosylated IgG1 monoclonal antibody targeting a chemokine receptor prevalent on Treg cells in the tumor microenvironment (TME); CHS-1000, an anti-ILT4 monoclonal antibody aimed at solid tumors; and GSK4381562, an antibody engineered to target CD112R on tumor cells. To support its endeavors, the company has forged several strategic alliances. These encompass a co-development and commercialization pact with Junshi Biosciences for toripalimab, as well as agreements with Surface and Adimab LLC. Its licensing portfolio includes arrangements with Bioeq AG, Genentech, Inc., Surface, and Vaccinex, Inc. Furthermore, Coherus has out-licensing agreements with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. Founded in 2010, the company currently operates as Coherus BioSciences, Inc., but is slated to officially rebrand as Coherus Oncology, Inc. in May 2025. Its headquarters are located in Redwood City, California.
CHRS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys meaningful progress across clinical and commercial fronts: robust enrollment across multiple studies, encouraging early TAGMO signals with biomarker directionality, solid commercial momentum for LOQTORZI (+15% QoQ sales) and sustained cost/liability reductions. Offsetting risks include a sizable quarter-over-quarter cash decline (~ -36.9%), an unachieved $37.5M milestone in Q2, immature clinical datasets that could change post-data cleaning, and ongoing commercial adoption/dosing frictions. On balance, the highlights (pipeline enrollment, early efficacy signals, revenue growth, expense reductions and liability improvements) outweigh the lowlights, though near-term execution and data maturation remain critical.View all CHRS earnings summariesCHRS Stock 12 Month Forecast
Average Price Target
$7.75
▲(465.69% Upside)
Technical Analysis
Ownership Overview
1.24% Insiders
9.35% Mutual Funds
8.62% Other Institutional Investors
72.35% Public Companies and
Individual Investors